Physician profile
John B Eberly
NPI 1093719320
$10,360.38
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,414 · 2020: $1,798 · 2021: $2,504 · 2022: $1,723 · 2023: $831 · 2024: $90.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,280.48 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,253.18 | 2019-2023 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $1,121.38 | 2019-2022 | |
| Novo Nordisk INC | $948.77 | 2019-2023 | Tresiba, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $891.76 | 2019-2023 | |
| Astrazeneca Pharmaceuticals Lp | $797.64 | 2019-2024 | Airsupra, Farxiga |
| Sanofi-Aventis U.S. LLC | $628.55 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $591.09 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $456.97 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $344.07 | 2019-2022 | |
| Allergan, INC. | $336.95 | 2019-2020 | |
| Lilly USA, LLC | $272.81 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $246.82 | 2021-2022 | |
| Pfizer INC. | $177.07 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.80 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $134.70 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $124.80 | 2019 | |
| Abbott Laboratories | $121.87 | 2022-2023 | Proclaim, Freestyle Libre 2, Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $108.72 | 2019-2023 | Trintellix |
| Glaxosmithkline, LLC. | $85.12 | 2021-2023 | Shingrix |
| Eisai INC. | $64.43 | 2021 | |
| Arbor Pharmaceuticals, INC. | $31.87 | 2019-2020 | |
| Antares Pharma, INC. | $26.23 | 2019-2020 | |
| Astellas Pharma US INC | $22.80 | 2019 | |
| Dexcom, INC. | $20.46 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $17.99 | 2023 | Cologuard Collection Kit |
| Metuchen Pharmaceuticals | $16.72 | 2019 | |
| Renalytix Ai, INC. | $13.89 | 2022 | |
| Horizon Therapeutics Plc | $13.72 | 2019 | |
| Adlon Therapeutics L.P. | $13.39 | 2021 | |
| Assertio Therapeutics, INC. | $12.86 | 2020 | |
| Corium, LLC | $11.77 | 2022 | |
| Daiichi Sankyo INC. | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eberly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.